NCT04689828 · OUTCOME

Radiographic Progression Free Survival 2 (rPFS2) by Blinded Independent Central Review (BICR)

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer · Source last updated 2026-08-26

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From date of crossover until second radiographic progression or death, whichever comes first, assessed up to approx. 32 months

What was measured

rPFS2 by BICR is defined as time from the date of crossover (ARDT to 177Lu-PSMA-617) to the date of radiographic disease progression by BICR or death from any cause for participants who crossover from ARDT arm to Lu-PSMA treatment.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2026-09
denom Units Selected: Participants
description: rPFS2 by BICR is defined as time from the date of crossover (ARDT to 177Lu-PSMA-617) to the date of radiographic disease progression by BICR or death from any cause for participants who crossover from ARDT arm to Lu-PSMA treatment.
reporting Status: NOT_POSTED
time Frame: From date of crossover until second radiographic progression or death, whichever comes first, assessed up to approx. 32 months
title: Radiographic Progression Free Survival 2 (rPFS2) by Blinded Independent Central Review (BICR)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice